 |
|
|
Gene Logic to Expand GeneExpress Suite Through Exclusive License to Protein Pathways from BioCarta Inc.
Exclusive Commercial-Use License to Protein Signal Transduction Pathways
Enables Refined Biological Context
GAITHERSBURG, MD & SAN DIEGO, CA, November 27, 2001 - Gene
Logic Inc. (Nasdaq:GLGC), a leading provider of biocontent and bioinformatics
solutions, today announced it has obtained an exclusive commercial-use license
to BioCarta Inc.'s broad and in-depth collection of signal transduction pathways
for use in visualizing protein interactions linked to Gene Logic's
GeneExpress(R) Suite of information products.
Under terms of the license agreement, Gene Logic will obtain multi-year access to BioCarta's pathways,
which will be directly linked with the existing gene expression content in the
GeneExpress(R) Suite. Gene Logic will have exclusive rights to utilize these
data in the context of a commercially available database product.
The Company plans to release access to approximately 150 of these biological
pathways with version 1.4 upgrade of its GeneExpress(R) Software System during
1H 2002. Financial details of the multi-year license agreement were not
disclosed.
The signal transduction pathways from BioCarta will provide a critical link between gene expression and protein interactions. More
specifically, they will provide functional insight to further understand the
relationship between disease initiation and progression and protein signaling
pathways involved in such processes.
In turn, this should enable further
target understanding and refined prioritization capabilities for current and
prospective pharmaceutical and biotechnology customers using the GeneExpress(R)
Suite.
Throughout the term of the agreement, BioCarta has agreed to provide hundreds of additional pathways and updates to existing pathways from
the scientific community, which constantly integrates emerging proteomic
information.
Commenting on the license agreement, Bethany J. Mancilla, Vice President, Corporate Development for Gene Logic said, "This agreement
illustrates our commitment to provide additional data-sets that complement and
expand the value and utility of our core gene expression data and its use as a
primary reference source for target discovery, target prioritization and
ultimately drug development. The combination of our comprehensive and
proprietary gene expression content and BioCarta's protein pathways provides the
basic infrastructure to enable researchers to conduct more biologically relevant
in-silico analysis, and positions Gene Logic for future expansion of relevant
content and the integration of other biologically significant data into the
GeneExpress(R) Suite of solutions."
BioCarta Overview
BioCarta Inc. is engaged in the development and commercialization of new technology for
functional proteomics. The Company currently offers over 10,000 reagents for the
study of protein function. BioCarta's unique web site (www.biocarta.com) serves
as an interactive web-based resource for life scientists.
The proteomic pathways presented on the site allow scientists to rapidly compare the function
of proteins across a number of model systems. BioCarta has offices in San Diego,
California, Hamburg, Germany, Oxford, United Kingdom, and Kobe, Japan to assure
comprehensive international linkage.
Regional offices ensure timely customer support and distribution of products, localized content, and
collaboration with life science researchers worldwide.
Gene Logic Overview
Gene Logic Inc. is a leading provider of biocontent and bioinformatics products related to gene activity in human disease and toxicity
to optimize rapid, reliable and cost-effective pharmaceutical and biotechnology
research and development.
Through the systematic and industrialized application of genomics, the Company provides a growing portfolio of genomic
information solutions based on its core database product, the GeneExpress(R)
Suite. For more information about Gene Logic, visit the Company's Web site at
www.genelogic.com or telephone toll-free - 800/GENELOGIC.
These statements involve estimates, assumptions and uncertainties that could cause
actual results to differ materially from those expressed in this press release.
These risks and uncertainties include, but are not limited to, the
extent of utilization of genomic information by the pharmaceutical and
biotechnology industries in research and product development, our ability to
retain existing and obtain additional database customers in a timely manner,
risks relating to the development of genomic database products and their use by
existing and potential customers and ultimate consumers, our reliance on
Affymetrix, Inc. for GeneChip microarrays and other sole source suppliers, our
ability to limit our losses and become profitable, our ability to timely supply
customers with customized and new products, continued access to necessary human
and animal tissue samples, the impact of technological advances and competition,
our ability to enforce our intellectual property rights, and the impact of
intellectual property rights of others, as well as other risks and uncertainties
included in our Annual Report on Form 10-K for the year ended December 31, 2000
and our Quarterly Reports on Form 10-Q filed with the Securities and Exchange
Commission.
|
|
|
